GlassScriptPhysician profile
Shane Edward Cook
NPI 1942694971
$5,565.00
in general payments reported to CMS, 2019-2025
25 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $281 · 2021: $793 · 2022: $736 · 2023: $1,084 · 2024: $1,229 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.95 |
| Education | $208.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,849.01 | 2020-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $770.62 | 2020-2025 | Tremfya |
| Amgen INC. | $436.95 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $328.72 | 2020-2024 | Ilumya |
| Lilly USA, LLC | $314.35 | 2020-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $246.43 | 2019-2024 | Libtayo |
| Genzyme Corporation | $227.65 | 2021-2023 | |
| Ucb, INC. | $178.14 | 2019-2025 | Bimzelx |
| Dermavant Sciences, INC. | $166.35 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.34 | 2022-2025 | Spevigo |
| Vector Surgical, LLC | $150.00 | 2021 | |
| Galderma Laboratories, L.P. | $125.68 | 2024-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.80 | 2024 | Cabtreo, Duobrii, Jublia |
| Incyte Corporation | $91.38 | 2023-2025 | Opzelura, Opzelura |
| Pfizer INC. | $78.27 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $75.38 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $59.96 | 2023-2024 | |
| Medtronic, INC. | $36.21 | 2024 | Closurefast |
| Blueprint Medicines Corporation | $33.53 | 2023 | |
| Biofrontera INC. | $22.32 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Exact Sciences Corporation | $21.53 | 2025 | Cologuard Collection Kit |
| Optinose US, INC. | $20.84 | 2020 | |
| Leo Pharma INC. | $18.94 | 2022 | |
| Averitas Pharma INC. | $18.47 | 2023 | Qutenza |
| Arcutis Biotherapeutics, INC. | $16.13 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.